Tanaka E, Taniguchi T, Sawa Y, Ohmori S, Kitada M, Horie T
Institute of Community Medicine, University of Tsukuba, Ibaraki-Ken, Japan.
Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Aug;120(2):317-20. doi: 10.1016/s0742-8413(98)10065-8.
The contribution of induced cytochrome P450 (P450) isozymes (CMLa; CYP2B, CMLb; CYP2A and CMLc; CYP3A) and related enzymes to trimethadione (TMO) metabolism in phenobarbital-treated rhesus monkey were investigated. The animals received a single dose of TMO (4 mg kg-1) and plasma samples were withdrawn before this administration and again at 0.08, 0.25, 0.5, 1 and 2 h later. Phenobarbital-treatment (20 mg kg-1 day-1 for 3 days; i.p.) significantly increased the plasma dimethadione (DMO)/TMO ratios at 0.08, 0.5, 1 and 2 h one's appropriate controls. Phenobarbital treatment also increased the P450 content (1.7-fold) and activity of aniline p-hydroxylase (1.3-fold), p-nitroanisole O-demethylase (1.8-fold) and benzphetamine N-demethylase (2.3-fold). The content of CMLa, CMLb and CMLc were increased about 12.8, 2.3 and 2.7-fold by phenobarbital pretreatment, respectively. The activity of TMO N-demethylation was inhibited by anti-P450 CMLa and anti-P450 CMLb. However, the anti-P450 CMLc antibody had no effect on this activity in liver microsomes. The results of both in vivo and in vitro studies of the effects of phenobarbital treatment on TMO metabolism indicate that these effects may be attributed to the induction of CMLa. These findings suggest that plasma DMO/TMO ratio in a single blood sampling after TMO administration is very useful for determination the degree of hepatic induction in clinical study.
研究了诱导型细胞色素P450(P450)同工酶(CMLa;CYP2B,CMLb;CYP2A和CMLc;CYP3A)及相关酶对苯巴比妥处理的恒河猴中三甲双酮(TMO)代谢的贡献。动物接受单次剂量的TMO(4 mg kg-1),在给药前及给药后0.08、0.25、0.5、1和2小时采集血浆样本。苯巴比妥处理(20 mg kg-1 每日一次,共3天;腹腔注射)显著提高了0.08、0.5、1和2小时时血浆二甲双酮(DMO)/TMO比值,与相应的对照组相比。苯巴比妥处理还增加了P450含量(1.7倍)以及苯胺对羟基化酶(1.3倍)、对硝基苯甲醚O-脱甲基酶(1.8倍)和苄非他明N-脱甲基酶(2.3倍)的活性。苯巴比妥预处理使CMLa、CMLb和CMLc的含量分别增加了约12.8、2.3和2.7倍。TMO N-脱甲基活性受到抗P450 CMLa和抗P450 CMLb的抑制。然而,抗P450 CMLc抗体对肝微粒体中的该活性没有影响。苯巴比妥处理对TMO代谢的体内和体外研究结果表明,这些影响可能归因于CMLa的诱导。这些发现表明,TMO给药后单次采血时的血浆DMO/TMO比值对于临床研究中确定肝脏诱导程度非常有用。